There is a small Australian company, PBTasx PRANnas, claiming to have reversed cognition loss in Alzheimers on the NTB scale of executive and trending toward ADAScog stat sig narrowly missing in just 12 weeks in 78 patients.
They released a paper last year showing an unknown use for the APP. It clears iron from neurons. Zinc build up in the synapses prevents the APP clearing the iron resulting in oxidization damage in the neurons.
Their trial result tends to indicate they are on the right path.
There are world class scientists with or advising them. Most of their work was done by Harvard Medical school and Melbourne(Aust) University.
Right now they are under the radar, and I cant understand why.
Once they have the planned 500+ patient trial underway, I would expect a big price move from a co with a market cap of 35m.
Hey, glad to have helped. Just keep in mind that if their science keeps proving itself, then everyone else is wrong and the Pran stock is going to $100. For the life of me I cant understand why a bio like LLY does not step up and partner.
lly has developed a fantastic tool for fighting Alzheimers. It will be used to identify AD in early stages where intervention is more likely to be effective. What would make it even more valuable would be a drug with a proven disease moditying action. By developing the tool LLY stand to benefit no matter who develops the drug. http://www.alzforum.org/new/detail.asp?id=2684 Check out this link on Prana's effort. http://www.youtube.com/watch?v=A2E7soyFXBY